Leukast

Montelukast, the active ingredient in Leukast, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma, exercise‑induced bronchoconstriction and allergic rhinitis in adults and children.

GNH USA supplies Leukast as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leukast (montelukast) is indicated for conditions involving leukotriene‑mediated airway inflammation.

- Asthma: improves control of persistent asthma and reduces frequency of exacerbations. - Exercise‑induced bronchoconstriction: prevents narrowing of airways during physical activity. - Allergic rhinitis: relieves nasal congestion, sneezing and itching associated with seasonal allergies.

Leukast may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate headache. - Upper respiratory infection: symptoms such as sore throat or nasal congestion. - Abdominal pain: mild stomach discomfort. - Cough: occasional dry cough.

Serious or Rare Side Effects: - Allergic reactions: rash, hives, swelling or anaphylaxis. - Mood changes: depression, suicidal thoughts or behavior. - Hepatotoxicity: elevated liver enzymes or hepatitis (rare).

When prescribing Leukast, clinicians should consider several precautionary measures.

- Pregnancy: Category B, use only if benefit outweighs risk. - Liver impairment: monitor hepatic function in patients with liver disease. - Concomitant asthma therapy: do not discontinue inhaled corticosteroids without medical advice. - Age considerations: safety in children under 12 months not established. - Drug interactions: review patient’s medication list for potential interactions. - Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Leukast can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Ritonavir: may increase montelukast plasma concentrations. - Phenobarbital: may reduce montelukast levels, decreasing effectiveness.

Moderate Interactions (Monitor Closely): - Fluconazole: may raise montelukast exposure modestly. - Carbamazepine: may lower montelukast concentrations. - Warfarin: monitor INR as montelukast may affect anticoagulation.